Menu

USDA Will Not Regulate CRISPR-Edited Crops

Restrictions will remain on transgenic plants, which contain artificially inserted genes from other species.

Apr 2, 2018
Diana Kwon

PIXABAY, ANALOGICUS

The US Department of Agriculture (USDA) will not regulate plants that have been modified through genome editing, according to statement released last week (March 28) by the agency.

In the announcement, the USDA states that it won’t oversee the use of genetically altered plants, as long as they could have also been developed through traditional breeding methods, such as cross-breeding or selecting for desirable properties. The agency adds that genome editing allows breeders to introduce new traits more precisely, and at a faster rate.

“With this approach, USDA seeks to allow innovation when there is no risk present,” US Secretary of Agriculture Sonny Perdue says in the statement. “Plant breeding innovation holds enormous promise for helping protect crops against drought and diseases while increasing nutritional value and eliminating allergens.” 

MIT Technology Review notes that transgenic crops—plants that contain artificially inserted genes from other species—will still be regulated.

See “The Unregulation of Biotech Crops

This announcement comes as good news to biotech companies using CRISPR to modify plants. According to Wired, this move will “[shave] years and tens of millions of dollars off the cost of developing a designer plant.”

“Having this consistent position enables smaller companies and academic labs to form this ecosystem of innovation to bring options to consumers,” Federico Tripodi, CEO of Calyxt, a Minnesota-based biotech that has already developed soybeans that produce oil low in trans fats that can be cooked at high heat, tells Wired.  

Whether gene-edited plants require special labeling is still unclear. “Bioengineered foods are defined by containing genetic material that could not otherwise have been conventionally bred or obtained in nature,” Deepti Kulkarni, a former member of the FDA’s Office of Chief Counsel who currently works at Sidley Austin, a corporate law firm in the U.S., tells Wired. “If USDA is construing the language this way, there is some suggestive signaling that these products might not be subject to disclosure.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Download this application note from ACEA Biosciences, Inc., to find out how to perform an immunophenotypic analysis of a human blood sample utilizing 13 fluorescent markers using a compact benchtop flow cytometer equipped with 3 lasers!